A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation Duchenne muscular dystrophy

被引：0
|
作者：
Riebling, P. [1 ]
Kong, R. [2 ]
O'Mara, E. [1 ]
Luo, X. [1 ]
Trifillis, P. [1 ]
Ong, T. [1 ]
机构：
[1] PTC Therapeut Inc, South Plainfield, NJ USA
[2] PTC Therapeut, South Plainfield, NJ USA
来源：
NEUROMUSCULAR DISORDERS | 2017年 / 27卷
关键词：
D O I：
10.1016/j.nmd.2017.06.446
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.406
引用
收藏
页码：S218 / S218
页数：1
相关论文
共 50 条
  • [31] ACT DMD: effect of ataluren on timed function tests in nonsense mutation Duchenne muscular dystrophy
    Bushby, K.
    Campbell, C.
    McDonald, C. M.
    Voit, T.
    Luo, X.
    Elfring, G.
    Kroger, H.
    Riebling, P.
    Ong, T.
    Spiegel, R.
    Peltz, S. W.
    Goemans, N.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S5 - S5
  • [32] Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy
    Landfeldt, Erik
    Lindberg, Christopher
    Sejersen, Thomas
    MUSCLE & NERVE, 2020, 61 (03) : 363 - 368
  • [33] Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry
    Muntoni, Francesco
    Desguerre, Isabelle
    Guglieri, Michela
    Nascimento Osorio, Andres
    Kirschner, Janbernd
    Tulinius, Mar
    Buccella, Filippo
    Elfring, Gary
    Werner, Christian
    Schilling, Traci
    Trifillis, Panayiota
    Zhang, Olivia
    Delage, Abdallah
    Santos, Claudio L.
    Mercuri, Eugenio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (14) : 1187 - 1200
  • [34] Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    McDonald, Craig M.
    Campbell, Craig
    Erazo Torricelli, Ricardo
    Finkel, Richard S.
    Flanigan, Kevin M.
    Goemans, Nathalie
    Heydemann, Peter
    Kaminska, Anna
    Kirschner, Janbernd
    Muntoni, Francesco
    Nascimento Osorio, Andres
    Schara, Ulrike
    Sejersen, Thomas
    Shieh, Perry B.
    Sweeney, H. Lee
    Topaloglu, Haluk
    Tulinius, Mar
    Vilchez, Juan J.
    Voit, Thomas
    Wong, Brenda
    Elfring, Gary
    Kroger, Hans
    Luo, Xiaohui
    McIntosh, Joseph
    Ong, Tuyen
    Riebling, Peter
    Souza, Marcio
    Spiegel, Robert J.
    Peltz, Stuart W.
    Mercuri, Eugenio
    LANCET, 2017, 390 (10101): : 1489 - 1498
  • [35] DEMOGRAPHICS AND SAFETY DATA FROM PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY RECEIVING ATALUREN IN THE STRATEGIC TARGETING OF REGISTRIES AND INTERNATIONAL DATABASE OF EXCELLENCE
    Muntoni, Francesco
    Buccella, Filippo
    Desguerre, Isabelle
    Kirschner, Janbernd
    Osorio, Andres Nascimento
    Tulinius, Mar
    Jiang, Joel
    Kristensen, Allan
    Able, Richard
    Trifillis, Panayiota
    Santos, Claudio
    MUSCLE & NERVE, 2020, 62 : S57 - S58
  • [36] A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy
    Landfeldt, Erik
    Sejersen, Thomas
    Tulinius, Mar
    ACTA PAEDIATRICA, 2019, 108 (02) : 224 - 230
  • [37] ACT DMD: Effect of Ataluren on Timed Function Tests (TFTs) in Nonsense Mutation Duchenne Muscular Dystrophy
    Goemans, Nathalie
    Campbell, Craig
    McDonald, Craig
    Voit, Thomas
    Luo, Xiaohui
    Elfring, Gary
    Kroger, Hans
    Riebling, Peter
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart
    Bushby, Katharine
    NEUROLOGY, 2016, 86
  • [38] IMPROVEMENTS IN MUSCLE FUNCTION AND ACCIDENTAL FALLING IN ATALUREN-TREATED PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY (DUCHENNE/BECKER MUSCULAR DYSTROPHY)
    Barth, J.
    McDonald, C. M.
    Henricson, E.
    Abresch, T.
    Reha, A.
    Elfring, G.
    Peltz, S.
    MUSCLE & NERVE, 2011, 44 (04) : 683 - 683
  • [39] Pretreatment Data from Phase 2b Study of Ataluren (PTC124™) in Nonsense Mutation Duchenne and Becker Muscular Dystrophy (nmDMD/BMD)
    Atkinson, L.
    Reha, A.
    Elfring, G. L.
    Finkel, R.
    Wong, B.
    Flanigan, K.
    McDonald, C. M.
    Bushby, K.
    Voit, T.
    Spinella, G.
    Cwik, V
    Miller, L. L.
    ANNALS OF NEUROLOGY, 2009, 66 : S139 - S140
  • [40] Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD)
    Finkel, R.
    Wong, B.
    Bushby, K.
    Reha, A.
    Elfring, G. L.
    Miller, L. L.
    Babiak, J.
    Morsy, M. A.
    Peltz, S.
    Welch, E.
    Atkinson, L.
    NEUROMUSCULAR DISORDERS, 2010, 20 (9-10) : 656 - 657
12345